Drug Pipeline Database & Screener

Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

"Phases" refer to the stage of drug development. The development process of a drug is as follows:

1) Preclinical trials - Animal testing to test safety.

2) Clinical trials - Testing on humans to test safety and efficacy. Generally there are three trials (Phase 1-3). Drugs to feature on BioPharmCatalyst are mainly in Phase 2 or 3 development. Phase 1 drugs are generally not included unless they are attached to a company with a small pipeline or considered blockbuster status. Over time, this list will grow.

3) FDA Review - If a drug successfully completes the clinical trial process the FDA will review the drug and decide whether to approve or not approve it. The FDA assigns a PDUFA goal date by which it will make its final decision.

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.

Visit the FDA Calendar for  latest Biotech Stock Catalyst dates (PDUFA dates and clinical data readouts).

Alternatively, the BioPharmCatalyst Biotech Stocks page provides data on daily price and volume movers and information on individual companies.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-25 minutes.

Showing 522 companies

Screener

Sort

Company Price Change Market Cap Outstanding Shares Short Ratio Updated

Stage

Any... Phase 1a Phase 1 Phase 1b Phase 1/2 Phase 2a Phase 2 Phase 2b Phase 2/3 Phase 3 NDA Filing sNDA Filing BLA Filing PDUFA PDUFA priority review Approved CRL

Indication

Any... 22q11.2 Deletion Syndrome Abdominal symptom claims (ASC) Achalasia Achondroplasia Achromatopsia Acid sphingomyelinase deficiency (ASMD) Acne Acquired thrombotic thrombocytopenic purpura (aTTP) Acromegaly Actinic keratosis Acute bacterial skin and skin structure infections (ABSSSI) Acute Coronary Syndrome Acute hepatic porphyrias Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Acute myocardial infarction (AMI) Acute otitis externa Acute Promyelocytic Leukemia Acute Respiratory Distress Syndrome Acute-on-Chronic Liver Failure (ACLF) Adenovirus ADHD Adrenoleukodystrophy (ALD) Adult Growth Hormone Deficiency (AGHD) Age-related macular degeneration (AMD) Agitation Alcohol Use Disorder Alcohol-induced liver decompensation (AILD) Alcoholic Hepatitis Alcoholic steatohepatitis (ASH) Alopecia areata Alpha-1 Antitrypsin deficiency (AATD) Alport Syndrome Alstrom Syndrome Alzheimer’s disease Ammonia Amyloidosis Amyotrophic Lateral Sclerosis (ALS) Anal cancer Anal fissures Anaphylaxis Androgenetic alopecia (AGA) Androgenic Alopecia Anemia Angelman syndrome Angiosarcoma Animal related Ankylosing spondylitis Anthrax Arginase I deficiency Asthma Atopic dermatitis Atopic keratoconjunctivitis atypical Hemolytic Uremic Syndrome (aHUS) Autism Auto-immune Hemolytic Anemia (AIHA) Autoimmune hemolytic anemia (AIHA) Autoimmune pulmonary alveolar proteinosis (PAP) Autosomal Recessive Stargardt Disease Axial Spondyloarthritis B-Cell Lymphoma Back pain Bacteremia Bardet-Biedl Syndrome Basal cell carcinoma Batten Disease Behcet's Disease Benign Prostatic Hyperplasia (BPH) Beta-Thalassemia Biliary Tract Cancer Biosimilar Bladder cancer Bladder pain syndrome/interstitial cystitis (BPS/IC) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Blindness Bowel related Brain cancer Brain injury Breast cancer Bronchiectasis Bulimia Bullous Pemphigoid Bunionectomy C. difficile Infection C3 glomerulopathy (C3G) Cachexia Candida Auris Candidemia Carcinoid Syndrome Carcinoma In-Situ (CIS) Cardiomyopathy Cardiovascular disease Cartilage/Knee Catecholamine-resistant hypotension (CRH) CDKL5 disorder Celiac disease Celluite Cervical cancer Cervical dysplasia Cervical dystonia Charcot-Marie-Tooth disease (CMT) Chemotherapy induced nausea and vomiting (CINV) Chemotherapy-induced neutropenia (CIN) Cholangiocarcinoma Choroideremia Chronic cough Chronic Dysphonia Chronic idiopathic constipation (CIC) Chronic Kidney Disease-Associated Pruritus Chronic Lymphocytic Leukemia (CLL) Chronic myelogenous leukemia Chronic myelomonocytic leukemia (CMML) Chronic obstructive pulmonary disease (COPD) Chronic Prostatitis Chronic Urticaria Cold agglutinin disease Colon cancer Colorectal cancer Community-acquired bacterial pneumonia (CABP) Complement-dependent Nephropathies (CDN) Complex regional pain syndrome (CRPS) Complicated intra-abdominal infections (cIAI) Complicated urinary tract infections (cUTI) Condyloma Congenital Adrenal Hyperplasia (CAH) Congenital hyperinsulinism Congenital Myasthenic Syndromes (CMS) Conjunctivitis Connective tissue growth factor (CTGF) Constipation Contact lens Contraception Coronary artery disease (CAD) Cow’s milk protein allergy (CMPA) Crigler-Najjar Critical limb ischemia (CLI) Crohn’s Disease Cushings syndrome Cutaneous fibrosis Cutaneous squamous cell carcinoma Cutaneous T-cell lymphoma (CTCL) Cystic fibrosis Cystinosis Cytomegalovirus (CMV) Degenerative cervical myelopathy (DCM) Dementia Depression Dermal scarring Dermatomyositis Developmental and Epileptic Encephalopathies (DEE) Diabetes Diabetic Foot Ulcers Diabetic macular edema (DME) Diabetic nephropathy Diabetic neuropathy Diabetic Retinopathy Diarrhea Diffuse Large B-Cell Lymphoma (DLBCL) Dravet Syndrome Dry eye disease Duchenne Muscular Dystrophy Ebola Eczema Egg Allergy Endometrial cancer Endometriosis Eosinophilic esophagitis Eosinophilic Gastritis Eosinophilic Granulomatosis with Polyangiitis (EGPA) Epidermolysis Bullosa Epilepsy Epithelioid Sarcoma Epstein-Barr virus (EBV-PTLD) Erectile dysfunction Esophageal cancer Esophagogastric adenocarcinoma Essential hypertension Essential thrombocythemia Essential tremor Exocrine pancreatic insufficiency (EPI) Fabry disease Facioscapulohumeral muscular dystrophy (FSHD) Factor Xa Familial amyloid polyneuropathy (FAP) Familial amyloidotic cardiomyopathy (FAC) Familial chylomicronemia syndrome (FCS) Familial partial lipodystrophy (FPL) Fanconi Anemia (FA) Fatty Acid Oxidation Disorders (FAOD) Female Sexual Arousal Disorder (FSAD) Female sexual dysfunction (FSD) Fibrodysplasia ossificans progressiva (FOP) Fibromyalgia Focal segmental glomerulosclerosis (FSGS) Follicular Lymphoma Forehead lines Fragile X syndrome Frailty Friedreich's Ataxia (FA) Friedreich’s ataxia (FA) Frozen Shoulder syndrome Gastric cancer Gastroenteritis Gastroesophageal reflux disease (GERD) Gastrointestinal stromal tumors (GIST) Gastroparesis Gaucher disease Generalized pustular psoriasis Geographic atrophy (GA) Gestational Trophoblastic Neoplasia (GTN) Giant cell arteritis (GCA) Glabellar lines Glaucoma Glioblastoma Multiforme (GBM) Glioma Glomerulopathies Glucocorticoid-induced osteoporosis (GIOP) Glut1 DS Glycogen Storage Disease GNE Myopathy Gout Graft versus host disease (GvHD) Growth hormone deficiency GSD1 Gynecomastia H. pylori Hair-related Head and Neck Cancer Headache Hearing loss Heart failure Heat stroke Hemochromatosis Hemophilia Hemophilia A Hemophilia B Hemorrhoids Hemostasis Hepatic porphyrias Hepatitis B Hepatitis C (HCV) Hepatitis delta virus (HDV) Hepatocellular carcinoma (HCC) Hepatorenal syndrome (HRS) Hereditary Angioedema (HAE) Hernia Herpes Heterozygous Familial Hypercholesterolemia (HeFH) Hidradenitis Suppurativa High Triglycerides Hip-related HIV Hodgkin lymphoma Homozygous familial hypercholesterolemia (HoFH) Hot flashes Human lipomas Human Papilloma Virus (HPV) Huntingtons disease Hutchinson-Gilford Progeria Syndrome (HGPS) Hyperammonemia Hypercholesterolemia Hypereosinophilic syndrome (HES) Hyperkalemia Hyperlipidemias Hyperoxaluria Hyperphosphatemia Hyperprolactinemia Hypertriglyceridemia Hyperuricemia Hypoactive sexual desire disorder (HSDD) Hypoglycemia Hypogonadism Hypoparathyroidism Hypotension Idiopathic Polypoidal Choroidal Vasculopathy Idiopathic pulmonary fibrosis (IPF) IgA nephropathy IgG4-Related Disease Immune Thrombocytopenic Purpura (ITP) Incisional complications Indolent Systemic Mastocytosis Infantile spasms (IS) Infections - various Inflammatory bowel disease (IBD) Influenza Inherited Metabolic Disorders (IMD) Insomnia Intermittent claudication (IC) Invasive aspergillosis Invasive candidiasis Irritable bowel syndrome (IBS) Jaundice Jet Lag Disorder Kidney disease Knee arthroplasty Lactose intolerance Lambert-Easton Myasthenic Syndrome (LEMS) Leber's Congenital Amaurosis (LCA) Lennox-Gastaut syndrome Leukemia Levodopa-Induced Dyskinesia Lipodystrophy Liposarcoma Liver cancer Liver Cirrhosis Liver disease Liver fibrosis Low Cardiac Output Syndrome Lung cancer Lung transplant rejection Lupus Lymphedema Lymphoma Macular Edema Malaria Malignant hyperthermia Mantle cell lymphoma (MCL) Marginal zone lymphoma Medullary thyroid cancer Melanoma Ménière's disease Menkes disease Merkel cell carcinoma MERS virus (Middle East Respiratory Syndrome) Mesothelioma Microsatellite Instability-High Cancer Migraine Mitochondrial Myopathy Molluscum Contagiosum Molybdenum cofactor deficiency (MoCD) MPS 7 MPS I MPS II MPS IIIA MPS IIIB MPS IVA Mucocutaneous candidiasis Multiple myeloma Multiple Osteochondroma (MO) Multiple Sclerosis (MS) Myasthenia Gravis (MG) Mydriasis Myelodysplastic syndromes (MDS) Myelofibrosis Myopia Narcolepsy Nasal polyps Nasopharyngeal carcinoma (NPC) Neuroblastoma Neuroendocrine tumors Neurogenic Orthostatic Hypotension (nOH) Neuromyelitis Optica Spectrum Disorder (NMOSD) Neuropathic pain Neutropenia Nicotine Addiction Niemann-Pick Disease Non-cystic fibrosis bronchiectasis (non-CF BE) Non-Hodgkin Lymphoma (NHL) Non-infectious uveitis Non-small cell lung cancer (NSCLC) Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Nonproliferative Diabetic Retinopathy Nontuberculous mycobacteria (NTM) Norovirus Obesity Obsessive compulsive disorder (OCD) Obstructive Sleep Apnea (OSA) Ocular Inflammation Oculopharyngeal Muscular Dystrophy Oncology Opioid dependence Opioid overdose Opioid-induced constipation (OIC) Oral Mucositis Ornithine Transcarbamylase (OTC) Deficiency Osteoarthritis Osteoporosis Other Otitis media Ovarian cancer Overactive Bladder (OAB) Pain Painful Lumbosacral Radiculopathy (PLSR) Pancreatic cancer Papulopustular Rosacea Parkinson’s disease Paroxysmal Nocturnal Hemoglobinuria (PNH) Peanut Allergy Pemphigus vulgaris (PV) Pericarditis Peripheral artery disease Peripheral Neuropathic Pain (PNP) Phenylketonuria (PKU) Pheochromocytoma Pigmented Villonodular Synovitis (PVNS) PKAN Plantar fasciitis Plaque psoriasis Plasma Plasminogen Deficiency Platelets Pneumonia Polycythemia Vera Pompe Disease Portal Hypertension Post-Bariatric Hypoglycemia (PBH) Post-herpetic neuralgia (PHN) Post-traumatic stress disorder (PTSD) Posterior Uveitis Postpartum depression (PPD) Prader-Willi Syndrome (PWS) Pre-term labor Preeclampsia Primary axillary hyperhidrosis Primary biliary cholangitis (PBC) Primary hyperoxaluria (PH) Primary Immune Deficiency Disease (PIDD) Primary immunodeficiency (PI) Primary ovarian insufficiency (POI) Primary sclerosing cholangitis (PSC) Progeria Progressive familial intrahepatic cholestasis (PFIC) Progressive supranuclear palsy (PSP) Prophylaxis Prostate cancer Proteus Syndrome Pruritus Pseudomonas aeruginosa Psoriasis Psoriatic arthritis Psychosis Pulmonary arterial hypertension (PAH) Pulmonary Hypertension Pyoderma Gangrenosum Pyruvate kinase deficiency Rare Bile Acid Synthesis Disorders Renal cancer Renal cell cancer (RCC) Respiratory syncytial virus (RSV) Retinal diseases Rett syndrome Rheumatoid Arthritis Richter's Transformation Rosacea S. aureus Sarcomas Schizophrenia Scleroderma Seborrheic keratosis (SK) Secondary hyperparathyroidism (SHPT) Secondary hypogonadism Seizures Severe aplastic anemia (SAA) Severe burns Sexual health (female) Sexual health (male) Sezary syndrome Shingles Short bowel syndrome Sickle disease Sinus related Sinusitis Sjögren-Larsson Syndrome (SLS) Small cell lung cancer (SCLC) Small lymphocytic lymphoma (SLL) Smallpox Smith-Magenis Syndrome Smoking cessation Social Anxiety Disorder (SAD) Soild tumors Solid tumors Spasticity Spinal muscular atrophy (SMA) Spinal muscular atrophy (SMA) Type 1 Spinal muscular atrophy (SMA) Type 2 Spinal muscular atrophy (SMA) Type 3 Spinal-related Spinocerebellar Ataxia Squamous Cell Carcinoma of the Head and Neck (SCCHN) Squamous cell lung cancer SRSE Staphylococcus aureus Status Epilepticus Stress related Stress urinary incontinence (SUI) Stroke Systemic mastocytosis (SM) Systemic Sclerosis T-cell lymphoma Tardive dyskinesia Testosterone related Thrombocytopenia Thrombotic microangiopathy (TMA) Thyroid cancer Thyroid Eye Disease (TED) Tinnitus Tourette syndrome Transfusion-dependent thalassemia (TDT) Transplant Transthyretin cardiomyopathy Trigeminal Neuralgia Tuberous Sclerosis Complex Tumor-induced osteomalacia (TIO) Type 1 diabetes Type 2 diabetes Ulcerative Colitis Urea Cycle Disorder Urinary tract infections Urothelial cancer Uterine Fibroids Vascular Ehlers-Danlos Syndrome Vasculitis Vasomotor symptoms (VMS) Veno-occlusive Disease (VOD) Venous Leg Ulcers Venous Thromboembolism (VTE) Vertigo Vitiligo Vulvovaginal candidiasis (VVC) Waldenström’s macroglobulinemia Walnut Allergy Warts Wet age-related macular degeneration (AMD) Women's health (pain/contraception) Wounds Wrinkles X-Linked Hypophosphatemia (XLH) X-Linked Myotubular Myopathy X-linked Retinitis Pigmentosa X-linked Retinitis Pigmentosa (XLRP) X-linked retinoschisis (XLRS) Zika

Market Cap

Any Mega ($200bln and more) Large ($10bln to $200bln) Mid ($2bln to $10bln) Small ($300mln to $2bln) Micro ($50mln to $300mln) Nano (under $50mln) +Large (over $10bln) +Mid (over $2bln) +Small (over $300mln) +Micro (over $50mln) -Large (under $200bln) -Mid (under $10bln) -Small (under $2bln) -Micro (under $300mln)

Price

Any Under $1 Under $2 Under $3 Under $4 Under $5 Under $7 Under $10 Under $15 Under $20 Under $30 Under $40 Under $50 Over $1 Over $2 Over $3 Over $4 Over $5 Over $7 Over $10 Over $15 Over $20 Over $30 Over $40 Over $50 Over $60 Over $70 Over $80 Over $90 Over $100 $1 to $5 $1 to $10 $1 to $20 $5 to $10 $5 to $20 $5 to $50 $10 to $20 $10 to $50 $20 to $50 $50 to $100

Short ratio

Any Low (<5 days) High (>20 days) Under 5 days Under 10 days Under 15 days Under 20 days Under 25 days Under 30 days Over 5 days Over 10 days Over 15 days Over 20 days Over 25 days Over 30 days

Relative Volume

Any Over 10 Over 5 Over 3 Over 2 Over 1.5 Over 1 Over 0.75 Over 0.5 Over 0.25 Under 2 Under 1.5 Under 1 Under 0.75 Under 0.5 Under 0.25 Under 0.1

Price to book

Any Low (<3) High (>50) Under 1 Under 2 Under 3 Under 4 Under 5 Under 6 Under 7 Under 8 Under 9 Under 10 Over 1 Over 2 Over 3 Over 4 Over 5 Over 6 Over 7 Over 8 Over 9 Over 10 Over 20 Over 30 Over 40 Over 50

FDA Calendar

Show Upcoming Catalysts

Apply Filters Reset Filters

Company

Price

Change

No of Shares

Market Cap

Short Ratio

Volume

Avg Daily Volume

Relative Volume

Price to Book

Open

Prev Close

EST EPCD

Updated

ABBV AbbVie Inc.

$92.26

-0.42  -0.45%

1.5 billion

$139.7 billion

6.25

9.8 million

5.8 million

1.7

-$41.37

$92.85

$92.68

09/21/2018

Tap to view 36 drug drugs

Drug	Indication	Stage	News
ABT-494 - SELECT-MONOTHERAPY	Rheumatoid arthritis	Phase 3	Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met.
Risankizumab	Ulcerative colitis	Phase 3	Phase 3 trial to be initiated 1H 2018.
ABT-494 - SELECT-COMPARE	Rheumatoid arthritis	Phase 3	Phase 3 data released April 9, 2018. Primary and secondary endpoints met.
ABT-414	Recurrent glioblastoma (rGBM)	Phase 1	Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 - SELECT-BEYOND	Rheumatoid arthritis	Phase 3	Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
Veliparib	Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)	Phase 3	Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib	Relapsed or refractory MCL mantle cell lymphoma	Approved	Approved November 13, 2013.
Imbruvica	Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy	Approved	Approved February 12, 2014.
Imbruvica	Deletion 17p	Approved	Approved July 19, 2014.
VIEKIRA PAK	HCV - genotype 1	Approved	Approved December 19, 2014.
IMBRUVICA	Waldenström’s Macroglobulinemia	Approved	Approved January 29, 2015 - PCYC
ABBV-8E12	Progressive supranuclear palsy (PSP)	Phase 2	Phase 2 initiation announced January 25, 2017.
ABBV-8E12	Alzheimer's disease	Phase 2	Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO)	Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)	Approved	Approval announced June 11, 2018.
Venetoclax	Relapsed or refractory multiple myeloma	Phase 3	Phase 3 trial initiated July 2016.
Venclexta	First-line Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial planned.
Venclexta	Follicular lymphoma (FL)	Phase 3	Phase 3 trial planned.
Risankizumab	Crohn’s Disease	Phase 3	Phase 3 trial to commence 2H 2017.
Risankizumab	Psoriasis	BLA Filing	Phase 3 data released October 26, 2017 - primary endpoints met. BLA filing announced April 25, 2018.
Imbruvica	Second-line Chronic graft-versus-host disease (GVHD)	Approved	Approval announced August 2, 2017.
ABT-494	Psoriatic Arthritis	Phase 3	Phase 3 trial to commenced 2017.
ABT-494 (upadacitinib) - SELECT-NEXT	Rheumatoid arthritis	Phase 3	Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Risankizumab	Psoriatic Arthritis	Phase 2b	Phase 3 trial planned for 2018.
ABT-494	Crohn’s Disease	Phase 3	Phase 3 trial initiated late 2017.
Rova-T (TRINITY)	Third-line Small Cell Lung Cancer	Phase 2	Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494	Atopic Dermatitis	Phase 3	Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica	Marginal zone lymphoma	Approved	sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P)	Hepatitis C virus (HCV)	Approved	Approval announced August 3, 2017.
Elagolix	Uterine Fibroids	Phase 3	Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018.
Elagolix	Endometriosis	Approved	FDA approval announced July 24, 2018.
ABT-494 - SELECT-EARLY	Rheumatoid arthritis	Phase 3	Phase 3 trial met all endpoints - June 5, 2018. Regulatory filing due 2H 2018.
Rova-T (TAHOE)	Second-line Small Cell Lung Cancer	Phase 3	Phase 3 data due 2020.
Rova-T (MERU)	First-line Small Cell Lung Cancer	Phase 3	Phase 3 data due 2020.
Imbruvica and Gazyva - iLLUMINATE	Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)	Phase 3	Phase 3 trial met PFS primary endpoint - May 24, 2018.
IMBRUVICA (ibrutinib)	Waldenström’s Macroglobulinemia	Approved	FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)	Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial did not meet primary endpoint - noted July 11, 2018.

ABEO Abeona Therapeutics Inc.

$12.62

-1.38  -9.82%

47.9 million

$605.3 million

26.98

3.2 million

477.9 thousand

6.73

$3.76

$13.95

$14.00

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ABO-101	Sanfilippo syndrome type B (MPS IIIB)	Phase 1/2	Phase 1/2 commencement of enrollment announced December 20, 2017.
EB-101	Recessive dystrophic epidermolysis bullosa (RDEB)	Phase 1/2	Phase 1/2 poster due at Society for Investigative Dermatology (SID) April 28, 2017. Noted January 29, 2018 intention to commence Phase 3 trial in 2018.
ABO-101	Recessive dystrophic epidermolysis bullosa (RDEB)	Phase 2	Phase 2 enrollment commenced September 2016.
ABO-102	Sanfilippo syndrome type A (MPS IIIA)	Phase 1/2	Phase 1/2 updated data released February 8, 2018. CSF heparan sulfate levels decreased 57%/64%.

ABIO ARCA biopharma Inc.

$0.51

-0.01  -2.63%

13.9 million

$7.1 million

0.08

539.5 thousand

1 million

0.52

$0.78

$0.52

$0.52

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Gencaro - GENETIC-AF trial	Chronic Heart Failure	Phase 2b	Phase 2b data released February 26, 2018 - no benefit shown in overall population. Noted July 31, 2018 that it intends to submit a SPA to the FDA for its Phase 3 trial in 3Q 2018.

ABLX Ablynx NV

$0.00

  +0.00%

78 million

$

0.09

57.5 thousand

0

$19.42

$0.00

$0.00

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ALX-0171	Respiratory syncytial virus (RSV)	Phase 2	Phase 2 trial initiation announced April 29, 2018. Data due 2H 2018.
Caplacizumab	Acquired thrombotic thrombocytopenic purpura (aTTP)	Phase 3	BLA filing due 1H 2018.
Vobarilizumab	Rheumatoid Arthritis	Phase 2b	Phase 2b completed. Awating opt-in decision from Abbvie expected 2018.
Vobarilizumab	Systemic lupus erythematosus (SLE)	Phase 2	Phase 2 trial did not meet primary endpoint - March 26, 2018.
ALX-0171	Infants Hospitalized for Respiratory Syncytial Virus	Phase 2b	Phase 2b data due 2H 2018.

ABUS Arbutus Biopharma Corporation

$9.50

-0.45  -4.52%

55.4 million

$526.3 million

4.87

258.2 thousand

446.9 thousand

0.58

$4.50

$9.90

$9.95

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ARB-1467, tenofovir, and pegylated interferon	Hepatitis B (HBV)	Phase 2	Phase 2 interim data due 4Q 2018.
AB-423 (MAD)	Hepatitis B (HBV)	Phase 2	Phase 2 trial to be initiated 1Q 2018.
ARB-1467	Hepatitis B (HBV)	Phase 2	Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
AB-452	Hepatitis B	Phase 1	Phase 1 trial to be initiated 4Q 2018 with trial completion slated for 3Q 2019.
AB-506	Hepatitis B (HBV)	Phase 1	Phase 1 data due 2Q 2019.

ACAD ACADIA Pharmaceuticals Inc.

$20.17

+1.06  +5.55%

125 million

$2.5 billion

6.43

14.7 million

2.5 million

5.86

$9.51

$20.10

$19.11

09/21/2018

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Pimavanserin - CLARITY	Adjunctive Treatment in Patients With Major Depressive Disorder	Phase 2	Phase 2 initiation announced December 1, 2016. Top-line data due 2H 2018.
Pimavanserin - Advance	Adjunctive treatment in patients with negative symptoms of schizophrenia	Phase 2	Phase 2 initiated November 2016. Data due 2019.
Pimavanserin - Enhance	Adjunctive treatment of schizophrenia	Phase 3	Phase 3 initiated November 2016. Data due 2019.
Pimavanserin - SERENE	Alzheimer’s disease agitation	Phase 2	Announced October 4, 2017 that trial will be discontinued.
Pimavanserin	Parkinson’s disease psychosis (PDP)	Approved	Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony	Alzheimer’s disease psychosis	Phase 3	Phase 3 trial initiation announced October 4, 2017.

ACER Acer Therapeutics Inc.

$30.94

+0.06  +0.19%

10.1 million

$311 million

1.06

110.9 thousand

57.2 thousand

1.94

$22.10

$31.18

$30.88

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
EDSIVO	Vascular Ehlers-Danlos Syndrome	Phase 3	NDA filing planned for 4Q 2018.
Tovaxin (Tcelna)	Secondary Progressive MS (SPMS)	Phase 2b	Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001	Urea cycle disorder (UCD)	Phase 2	NDA filing planned for 2019.

ACHN Achillion Pharmaceuticals Inc.

$3.51

-0.03  -0.85%

138.6 million

$486.4 million

5.48

3.4 million

1.1 million

3.06

$1.65

$3.44

$3.54

09/21/2018

Tap to view 7 drug drugs

Drug	Indication	Stage	News
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	Phase 2 interim data due December 2018.
JNJ-4178	Hepatitis C (HCV)	Phase 2a	Janssen noted September 11, 2017 that no further development planned.
ACH-4471	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 2	Phase 2 initiation announced April 6, 2017. Interim data due December 2018.
JNJ-4178 - OMEGA-1	Hepatitis C (HCV)	Phase 2b	Janssen noted September 11, 2017 that no further development planned.
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	Phase 2 longer duration data due 2H 2018.
ACH-5228	Healthy volunteers	Phase 1	Phase 1 data due 4Q 2018.
ACH-5548	Healthy volunteers	Phase 1	Phase 1 trial initiation announced July 10, 2018. Interim data due 2H 2018.

ACHV Achieve Life Sciences Inc.

$2.49

-0.07  -2.73%

4.6 million

$11.3 million

4.1

72.6 thousand

112.3 thousand

0.65

$0.69

$2.57

$2.56

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Cytisine	Smoking cessation	Phase 2b	Phase 2b trial to be initiated 4Q 2018 with data due 3Q 2019.

ACIU AC Immune SA

$8.60

+0.16  +1.90%

67.4 million

$579.3 million

10.45

80.2 thousand

230.1 thousand

0.35

$5.89

$8.53

$8.44

09/21/2018

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Crenezumab - CREAD 2	Alzheimer’s disease	Phase 3	Second Phase 3 trial initiation announced February 28, 2017. Noted July 16, 2018 that trial is fully recruited. Data due 2021.
RO7105705	Alzheimer’s disease	Phase 1b	Phase 2 commencement of dosing announced November 2, 2017.
ACI-24 (anti-Abeta vaccine)	Alzheimer's disease-like characteristics in individuals with Down syndrome	Phase 1/2	Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due late-2018. Completion of recruitment for high dose cohort announced August 20, 2018.
Crenezumab - CREAD 1	Alzheimer’s disease	Phase 3	Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
ACI-24	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced August 20, 2018.
ACI-35	Alzheimer’s disease	Phase 1b	Phase 2 trial planned.

ACOR Acorda Therapeutics Inc.

$18.20

+0.05  +0.28%

47.5 million

$864.2 million

11.57

3.8 million

616.7 thousand

6.13

$1.42

$18.15

$18.15

09/21/2018

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Ampyra	Improve walking in patients with multiple sclerosis		Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-427	Migraine	Phase 1	Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Tozadenant	Parkinson’s disease (PD)	Phase 3	Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine	Post stroke deficits	Phase 3	Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301)	OFF episodes of Parkinson’s disease (PD)	PDUFA	Refuse-To-File letter August 30, 2017. New PDUFA date October 5, 2018 extended to January 5, 2018.
BTT1023	Primary Sclerosing Cholangitis	Phase 2	Phase 2 data due 2Q 2018 (overdue - shifted to 3Q in calendar).

ACRS Aclaris Therapeutics Inc.

$15.17

-0.26  -1.69%

31 million

$470 million

15.09

393.3 thousand

241.4 thousand

1.63

$2.70

$15.47

$15.43

09/21/2018

Tap to view 9 drug drugs

Drug	Indication	Stage	News
ATI-502 (AA-201 Topical) - dose ranging	Alopecia areata	Phase 2	Phase 2 data due 1H 2019.
ATI-502 (VITI-201 Topical)	Vitiligo	Phase 2	Phase 2 open label trial initiation announced December 19, 2017 with data due 1H 2019.
ATI-502 AUATB-201 - open label	Alopecia areata - regrowth of eyebrows	Phase 2	Phase 2 trial ongoing.
ATI-501 (AUAT-201 Oral)	Alopecia areata	Phase 2	Phase 2 trial initiation announced June 26, 2018 with data due 2H 2019.
ESKATA (hydrogen peroxide)	Seborrheic keratosis (SK)	Approved	Approval announced December 15, 2017.
A-101	Common warts (verruca vulgaris)	Phase 2	Phase 2 data released January 8, 2018 - endpoints met. Phase 3 trial to be initiated 2H 2018.
ATI-502 AA-202 Topical - PK/safety	Alopecia areata	Phase 2	Phase 2 interim data released June 28, 2018.
ATI-502 - open label	Androgenetic alopecia (AGA) - Hair loss	Phase 2	Phase 2 data due 1H 2019.
ATI-502	Atopic dermatitis (AD)	Phase 2	Phase 2 data due mid-2019.

ACRX AcelRx Pharmaceuticals Inc.

$3.95

+0.25  +6.76%

60.6 million

$239.4 million

6.01

1.5 million

672.1 thousand

2.26

-$4.88

$3.75

$3.70

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ARX-04 (SAP302)	Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury	Phase 3	Phase 3 data released August 15 2016
DSUVIA (ARX-04)	Moderate-to-severe acute pain following a surgical procedure	PDUFA	CRL issued October 12, 2017. New PDUFA date November 3, 2018 with Advisory Committee Meeting October 12, 2018.
Zalviso	Post-operative pain following open abdominal surgery and hip or knee replacement surgery	Phase 3	CRL Jul 26 2014. Additional clinical trial required. Data released August 1, 2017. NDA resubmission due 2H 2018.

ACST Acasti Pharma Inc.

$0.59

+0.02  +3.76%

36.7 million

$21.6 million

2.06

52.3 thousand

184.1 thousand

0.28

$3.40

$0.57

$0.57

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
CaPre (TRILOGY trial)	Hypertriglyceridemia	Phase 3	Phase 3 top-line data due by the end of 2019.

ADAP Adaptimmune Therapeutics plc

$11.71

-0.26  -2.17%

104.4 million

$1.2 billion

5.82

272.2 thousand

435.7 thousand

0.62

$7.41

$11.95

$11.97

09/21/2018

Tap to view 8 drug drugs

Drug	Indication	Stage	News
NY-ESO T-cell therapy	Synovial sarcoma - cancer	Phase 1/2	Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy	Ovarian cancer	Phase 1/2	Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy	Myxoid round cell liposarcoma (MRCLS)	Phase 1/2	Phase 1/2 data released ASCO June 2018 - 3 PRs, 1 unconfirmed PR, 3 SD out of 8 patients.
NY-ESO T-cell therapy	Myeloma	Phase 1/2	Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 initiated November 2015. Data are due 2017.
MAGE-A4	Soild tumors	Phase 1	Phase 1 response data due 2H 2018.
AFP	Hepatocellular carcinoma	Phase 1	Initial safety data due late 2018.
MAGE-A10	Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Phase 1 response data due 2H 2018.

ADIL Adial Pharmaceuticals Inc

$2.90

-0.04  -1.36%

6.5 million

$19 million

0.28

18.6 thousand

24.9 thousand

0.75

-$14.50

$3.16

$2.94

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AD04	Alcohol use disorder	Phase 3	Phase 3 European trial planned. US trials not planned.

ADMA ADMA Biologics Inc

$6.15

-0.42  -6.39%

46.3 million

$285 million

7.76

340 thousand

275.2 thousand

1.24

$5.49

$6.55

$6.57

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
RI-002	Primary Immune Deficiency Diseases	BLA Filing	CRL issued July 29 2016. BLA to be resubmitted September 2018.
BIVIGAM	Primary humoral immunodeficiency	PDUFA	PDUFA date October 25, 2018.

ADMP Adamis Pharmaceuticals Corporation

$3.10

+0.05  +1.64%

47.3 million

$146.6 million

2.93

1.9 million

800.6 thousand

2.42

$5.74

$3.10

$3.05

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Epinephrine Pre-filled Syringe (PFS)	Emergency treatment of anaphylaxis.	Approved	CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000	Asthma/COPD	Phase 2	Phase 3 planned for 4Q 2018.
Symjepi - low dose	Anaphylaxis	PDUFA	sNDA filing to include lower dose. PDUFA date September 27, 2018.
APC-6000	Opioid overdose	NDA Filing	NDA filing due YE 2018.

ADMS Adamas Pharmaceuticals Inc.

$19.17

-0.51  -2.59%

27.2 million

$521.2 million

12.12

1.4 million

542.1 thousand

2.64

$3.66

$19.71

$19.68

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ADS-4101	Partial onset seizures in patents with epilepsy	Phase 1b	Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
GOCOVRI (amantadine)	Multiple sclerosis (MS)	Phase 3	Phase 3 commencement of enrollment announced April 3, 2018. Enrollment to be completed 2H 2019.
Namzaric	Moderate to severe dementia of the Alzheimer's type.	Approved	Approved December, 24 2014.
ADS-5102	Levodopa-Induced Dyskinesia	Approved	Approval announced August 24, 2017.
GOCOVRI (amantadine)	Dyskinesia patients with Parkinson's disease	Phase 3	Phase 3 open-label data released April 19, 2018.

ADRO Aduro Biotech Inc.

$6.20

-0.1  -1.59%

79.1 million

$490.2 million

16.85

1 million

326.9 thousand

3.2

$2.78

$6.25

$6.30

09/21/2018

Tap to view 9 drug drugs

Drug	Indication	Stage	News
BION-1301	Multiple Myeloma	Phase 1/2	Phase 1/2 initiation announced December 18, 2017.
ADU-S100	Solid tumors or lymphomas	Phase 1b	Initial data due 2H 2018.
CRS-207 and GVAX Pancreas - ECLIPSE trial	Pancreatic cancer	Phase 2b	Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial	Pancreatic cancer	Phase 2b	Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab	Mesothelioma - cancer	Phase 2	Noted December 12, 2017 that development to be discontinued.
ADU-S100 and PDR001	Solid tumors or lymphomas	Phase 1b	Initial data due 2H 2018.
pLADD	Colorectal Cancer	Phase 1	Phase 1 additional additional immunological data due by end of 2018.
pLADD	Colorectal Cancer	Phase 1	Phase 1 additional additional immunological data due by end of 2018.
ADU-214 with Nivolumab	Non-Small Cell Lung Cancer	Phase 1/2	Phase 1b initiation announced June 7, 2018.

ADVM Adverum Biotechnologies Inc.

$5.90

+0.15  +2.61%

62.7 million

$369.9 million

6

1.2 million

528.3 thousand

2.35

$1.59

$6.05

$5.75

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
ADVM-043	Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/2	Phase 1/2 commencement of dosing announced December 28, 2017 with preliminary data due 2H 2018.
AVA-101	Wet age-related macular degeneration (Wet-AMD)	Phase 2a	Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.

ADXS Advaxis Inc.

$0.86

+0.03  +4.23%

69.5 million

$59.7 million

6.71

708.1 thousand

1 million

0.69

$1.79

$0.83

$0.82

09/21/2018

Tap to view 8 drug drugs

Drug	Indication	Stage	News
Axalimogene filolisbac + durvalumab	Recurrent or refractory HPV-associated cervical cancer and head & neck cancer	Phase 1/2	Clinical hold announced March 2018 released July 13, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046	Castrate-resistant prostate cancer	Phase 1/2	Part B monotherapy data due 1Q 2019.
Axalimogene filolisbac - AIM2CERV Trial	High-risk, locally advanced cervical cancer	Phase 3	Announced Phase 3 first patient dosed - February 6, 2017. Noted June 7, 2018 that unless partner is found soon trial will be terminated.
Axalimogene filolisbac - GOG 0265 study	Cervical cancer	Phase 2	Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
ADXS-HER2	HER2-driven malignancies - cancer	Phase 1b	Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac	Anal cancer (FAWCETT)	Phase 2	Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO	Non-small cell lung cancer (NSCLC)	Phase 1	Phase 1 initiation of dosing announced June 11, 2018. Data from initial cohort due 2019.
ADXS-503	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 trial to be initiated by the end of 2018.

AERI Aerie Pharmaceuticals Inc.

$58.45

+0.1  +0.17%

45.2 million

$2.6 billion

9.75

802.1 thousand

389.5 thousand

2.06

$13.56

$58.45

$58.35

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Roclatan	Glaucoma	PDUFA	PDUFA date March 14, 2019.
Rhopressa	Glaucoma	Approved	PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.

AEZS Aeterna Zentaris Inc.

$1.73

-0.01  -0.57%

16.4 million

$28.4 million

6.32

33.1 thousand

62.9 thousand

0.53

$3.00

$1.75

$1.74

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Macimorelin Acetate - Macrilen	Adult Growth Deficiency	Approved	CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex	Endometrial cancer	Phase 3	Phase 3 trial did not meet primary endpoint - May 1, 2017.

AFMD Affimed N.V.

$4.38

+0.03  +0.57%

62.4 million

$273 million

0.39

911.1 thousand

2.3 million

0.4

$4.97

$4.35

$4.35

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AFM13 with Keytruda	Hodgkin Lymphoma - Cancer	Phase 1b	Phase 1b updated data due 4Q 2018.
AFM13	Hodgkin Lymphoma - Cancer	Phase 2	Phase 2a ongoing.
AFM13	CD30-positive lymphoma	Phase 1/2	Phase 1b/2a updated data due 4Q 2018.

AGEN Agenus Inc.

$2.00

-0.1  -4.76%

113.3 million

$226.6 million

6.63

2.2 million

1.3 million

1.65

-$2.02

$2.11

$2.10

09/21/2018

Tap to view 7 drug drugs

Drug	Indication	Stage	News
AGEN2034 and AGEN1884	Solid tumors	Phase 1/2	Phase 1/2 enrollment has been completed - noted January 22, 2018.
AGEN1884 (anti-CTLA-4)	Solid cancers	Phase 1	Phase 1 presentation at ASCO 2018. 31% ORR.
Shingrix	Shingles	Approved	Approval announced October 20, 2017.
AGEN2034 (anti-PD-1)	Cervical cancer	Phase 1/2	Phase 1/2 enrollment has been completed - noted January 22, 2018. Data due 4Q 2019.
INCAGN1949	Solid tumors - cancer	Phase 1/2	Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1876	Solid tumors - cancer	Phase 1/2	Phase 1/2 trial commenced June 2016
AGEN 1884 plus Keytruda	Non-small cell lung cancer (NSCLC)	Phase 2	Phase 2 data due 2018.

AGIO Agios Pharmaceuticals Inc.

$73.56

-0.41  -0.55%

58 million

$4.3 billion

14.84

503.7 thousand

342 thousand

1.47

$5.18

$74.23

$73.97

09/21/2018

Tap to view 12 drug drugs

Drug	Indication	Stage	News
AG-348	Thalassemia	Phase 2	Phase 2 trial to be initiated 4Q 2018.
Ivosidenib	IDH1m Relapsed/Refractory AML - cancer	Approved	FDA Approval announced July 20, 2018.
AG-348	Pyruvate kinase deficiency	Phase 3	Phase 3 trial initiation announced June 18, 2018.
AG-120 and VIDAZA - AGILE	Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer	Phase 3	Phase 3 initiated 2Q 2017.
Enasidenib (AG-221) - IDHENTIFY	Refractory Acute myeloid leukemia (AML) - cancer	Phase 3	Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221	Advanced hematologic malignancies with an IDH2 mutation	Approved	Approval announced August 1, 2017.
AG-120 Ivosidenib	IDH1 mutant positive cholangiocarcinoma - cancer	Phase 3	Phase 3 initiated December 2016. Enrollment to be completed 1H 2019.
AG-120 Ivosidenib	R/R Acute Myeloid Leukemia (AML)	Phase 1	Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA	Frontline AML with IDH1 or IDH2 mutation	Phase 1/2	Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Ivosidenib or enasidenib	Frontline AML with IDH1 or IDH2 mutation	Phase 1	Phase 1 first data presented at ASH 2017 with updated data due at ASH 2018. Phase 3 trial to be initiated 4Q 2018.
AG-270	Solid tumors	Phase 1	Phase 1 dosing of first patient announced March 19, 2018.
AG-881	Glioma	Phase 1	Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients.

AGLE Aeglea BioTherapeutics Inc.

$9.16

+0.43  +4.93%

22 million

$201.5 million

3.46

410.9 thousand

189.9 thousand

2.16

$2.74

$8.73

$8.73

09/21/2018

Tap to view 7 drug drugs

Drug	Indication	Stage	News
AEB1102 + KEYTRUDA	Small cell lung cancer (SCLC)	Phase 1/2	Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102	Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)	Phase 1	Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102)	Arginase I deficiency	Phase 1/2	Pivotal trial planned for 1H 2019.
AEB1102	Solid tumors	Phase 1	Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102)	Solid tumors	Phase 1	Phase 1 data to be presented at ESMO October 19-23, 2018.
Pegzilarginase (AEB1102) + KEYTRUDA	Small cell lung cancer (SCLC)	Phase 1/2	Phase 1/2 top-line safety and clinical data due 4Q 2018.
AEB1102	Solid tumors	Phase 1	Monotherapy data due 4Q 2018.

AGN Allergan plc

$191.31

-1.2  -0.62%

339.4 million

$64.9 billion

2.07

5.9 million

1.7 million

3.39

$0.91

$192.60

$192.51

09/21/2018

Tap to view 26 drug drugs

Drug	Indication	Stage	News
Botox	Forehead lines	Approved	Approval (third indication) announced October 3, 2017.
ABP 980	Herceptin biosimilar	BLA Filing	BLA filing announced July 31, 2017.
RTGel in combination with BOTOX	Overactive Bladder (OAB)	Phase 2	Phase 2 data due 2019.
JUVÉDERM VOLLURE	Correction of moderate to severe facial wrinkles and folds	Approved	Approval announced March 20, 2017.
Brazikumab	Crohn's disease	Phase 2b	Phase 3 to be initiated 2H 2018.
Bimatoprost	Androgenic Alopecia	Phase 3	Phase 3 enrollment to be completed 2H 2018.
Botox	Depression	Phase 2	Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Cariprazine	Bipolar I depression	Phase 3	Phase 3 data released December 18, 2017 - primary endpoint met.
RORγt agonist	Psoriasis	Phase 2b	Phase 2b trial ongoing.
Cariprazine	Maintenance Treatment of Schizophrenia	Approved	Approval announced November 13, 2017.
ATOGEPANT	Prophylaxis (migraine)	Phase 2b	Phase 2b top-line data released June 11, 2018 - primary endpoint met. Phase 3 trial to be initiated 1H 2019.
UBROGEPANT	Acute (migraine)	Phase 3	Phase 3 data released February 6, 2018 - primary endpoints met.
RAPASTINEL	Major depressive disorder (MDD)	Phase 3	Phase 3 initiated October 2016. Data due 1H 2019.
RELAMORELIN	Diabetic Gastroparesis	Phase 3	Phase 3 initiated 2H 2017 with top-line data due 2020.
ESMYA (ulipristal acetate)	Uterine Fibroids	CRL	CRL issued August 21, 2018.
ABICIPAR	Diabetic macular edema (DME)	Phase 3	Phase 3 trial to be initiated 2H 2018.
Cenicriviroc (CVC)	Nonalcoholic steatohepatitis (NASH)	Phase 3	Phase 3 trial has been initiated.
ABICIPAR	Age-related macular degeneration (AMD)	Phase 3	Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI)	Approved	sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0%	Facial Erythema (Redness) Associated with Rosacea	Approved	Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults	Chronic idiopathic constipation (CIC)	Approved	sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	Approved	Approved September 14, 2017.
Sarecycline	Severe acne vulgaris	PDUFA	PDUFA date 4Q 2018. Exact date not provided by company. Estimate October 19, 2018 based on NDA acceptance date of December 20, 2017.
Cariprazine	Bipolar I Depression	Phase 3	Phase 3 data released April 3, 2018. Primary endpoint met. sNDA filing due 2H 2018.
UBROGEPANT - ACHIEVE II (UBR-MD-02)	Migraine	Phase 3	Phase 3 data due released April 27, 2018. High dose met both primary endpoints. Low dose met one of two.
Brazikumab	Ulcerative colitis	Phase 2	Phase 2 trial to be initiated 2H 2018.

AGRX Agile Therapeutics Inc.

$0.34

-0.02  -4.90%

34.4 million

$11.6 million

0.95

687.3 thousand

2 million

0.34

$0.44

$0.36

$0.35

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Twirla	Contraceptive patch	CRL	CRL issued 2013. Further CRL issued December 22, 2017. Noted May 18, 2018 that FDA will require further trials for resubmission to take place.

AGTC Applied Genetic Technologies Corporation

$4.40

  +0.00%

18.1 million

$79.8 million

2.77

227.2 thousand

79.9 thousand

2.84

$0.80

$4.45

$4.40

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AAV Gene Therapy	CNGB3 Achromatopsia	Phase 1/2	Phase 1/2 dose escalation part of trial to be completed 1Q 2019.
rAAV-hRS1	X-linked retinoschisis (XLRS)	Phase 1/2	Phase 1/2 data due 4Q 2018.
AAV-based gene therapy	X-linked Retinitis Pigmentosa (XLRP)	Phase 1/2	Phase 1/2 dose escalation part of trial to be completed 1Q 2019.

AIMT Aimmune Therapeutics Inc.

$27.21

-0.05  -0.18%

58.5 million

$1.6 billion

15.71

2 million

370.5 thousand

5.47

$5.53

$27.30

$27.26

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AR101 ARTEMIS	Peanut Allergy	Phase 3	Phase 3 enrollment has commenced - noted June 5, 2017. Data due 1H 2019.
AR101 RAMSES	Peanut Allergy	Phase 3	Phase 3 initiation announced May 11, 2017. Data due 2H 2018.
AR101 PALISADE	Peanut Allergy	Phase 3	Phase 3 data released February 20, 2018 met primary endpoint. BLA filing due 2018.
AR 201	Egg Allergy	Phase 2	Phase 2 trial to be initiated 1H 2019.
AR 301	Walnut Allergy	Phase 2	Phase 2 trial to be initiated 2H 2019.

AKAO Achaogen Inc.

$4.20

-0.11  -2.55%

45.2 million

$189.9 million

15.49

4.7 million

842 thousand

5.53

$3.23

$4.30

$4.31

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
C-Scape	Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens	Phase 3	Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
Plazomicin	Complicated urinary tract infections (cUTI)	Approved	FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin - CARE	Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)	Phase 3	Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.

AKBA Akebia Therapeutics Inc.

$8.28

-0.05  -0.60%

57 million

$472.3 million

7.45

1.1 million

452.3 thousand

2.49

$2.85

$8.49

$8.33

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Vadadustat - TRILO2GY	Three-times-weekly dosing regimen for vadadustat	Phase 3	Phase 3 trial to be initiated in late 2018 or early 2019, with top-line results expected in early 2020.
Vadadustat - FO2RWARD	Renal anemia	Phase 2	Phase 2 trial data due 1H 2019.
Vadadustat - INNO2VATE	Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)	Phase 3	Phase 3 data due 4Q 2019 or 1Q 2020.
Vadadustat - PRO2TECT	Non-dialysis patients with anemia related to CKD (NDD-CKD)	Phase 3	Phase 3 data due mid-2020.

AKCA Akcea Therapeutics Inc.

$27.98

-0.94  -3.25%

85.7 million

$2.4 billion

19.57

447.9 thousand

323 thousand

1.39

$8.25

$29.07

$28.92

09/21/2018

Tap to view 8 drug drugs

Drug	Indication	Stage	News
AKCEA-ANGPTL3-LRx	Rare hyperlipidemias	Phase 2	Phase 2b initiated.
AKCEA-ANGPTL3-LRx	Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus	Phase 2	Phase 2 initiation announced December 14, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx	Hyperlipoproteinemia and established cardiovascular disease	Phase 2b	Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APO(a)-LRx	Hyperlipoproteinemia(a) and established cardiovascular disease	Phase 2b	Phase 2b completion of enrollment announced February 7, 2018. Data due 2H 2018.
Inotersen (IONIS-TTRRx)	NEURO-TTR - familial amyloid polyneuropathy (FAP).	PDUFA priority review	Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review extended to October 6, 2018.
Volanesorsen - APPROACH	Familial chylomicronemia syndrome (FCS)	CRL	CRL issued August 27, 2018.
Volanesorsen	Partial lipodystrophy rapidly	Phase 3	Phase 3 initiated November 2015
Volanesorsen	Familial partial lipodystrophy (FPL)	Phase 3	Phase 3 initiated November 2015

AKTX Akari Therapeutics Plc

$2.11

+0.02  +0.96%

15.3 million

$32.2 million

9.33

15.1 thousand

44.6 thousand

0.34

$1.97

$2.06

$2.09

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Coversin	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 2	Phase 2 interim data released April 24, 2017. Further update December 8, 2017 noted that primary endpoint was met. Phase 3 program to commence late 1Q 2018.
Coversin	Atopic keratoconjunctivitis	Phase 1	Phase 2 trial to be initiated 1H 2018.
Coversin	Bullous Pemphigoid	Phase 1	Phase 2 trial to be initiated 1H 2018.
Coversin	Atypical hemolytic-uremic syndrome (aHUS)	Phase 1	Phase 2 trial initiated late 2017.

ALBO Albireo Pharma Inc.

$31.44

-1.26  -3.85%

12 million

$376.3 million

8.16

121.5 thousand

46.5 thousand

2.61

$2.52

$31.50

$32.70

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
A4250	Progressive familial intrahepatic cholestasis (PFIC)	Phase 2	Phase 3 trial to be initiated spring 2018.
A4250 - PEDFIC- 1	Liver disease	Phase 2	Phase 3 top-line data due late 2019 or early 2020.

ALDR Alder BioPharmaceuticals Inc.

$16.10

-0.2  -1.23%

68.2 million

$1.1 billion

13.22

1.3 million

786.9 thousand

1.71

$4.59

$16.25

$16.30

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ALD403 - PROMISE 2	Frequent episodic migraine	Phase 3	Phase 3 PROMISE 2 data released January 8, 2017 - endpoints met. 6-mth data to be presented June 29, 2018 noted 43% of patients achieved 75% or greater reduction of monthly migraine days. PK Comparability Study 4Q 2018. BLA filing due 1Q 2019.
ALD403	Chronic Migraine	Phase 2b	Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1	Frequent episodic migraine	Phase 3	Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.

ALDX Aldeyra Therapeutics Inc.

$9.10

+0.6  +7.06%

21 million

$190.9 million

5.17

440.8 thousand

82.2 thousand

5.36

$5.17

$8.45

$8.50

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ADX-102	Dry eye syndrome	Phase 2b	Phase 2b data due late 3Q or early 4Q 2018.
Reproxalap (ADX-102)	Allergic conjunctivitis	Phase 3	Phase 3 data due late 2018 or early 2019.
ADX-102	Noninfectious anterior uveitis	Phase 3	Phase 3 data due 2019.
ADX-102	Sjögren-Larsson Syndrome (SLS)	Phase 3	Phase 3 initial data due in 2019.

ALIM Alimera Sciences Inc.

$1.04

-0.04  -3.70%

70 million

$72.8 million

5.96

144.8 thousand

154.2 thousand

0.94

-$1.16

$1.07

$1.08

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Iluvien	Diabetic macular edema	Approved	CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014

ALKS Alkermes plc

$41.56

+0.45  +1.09%

155.3 million

$6.5 billion

15.84

1.4 million

553.9 thousand

2.53

$5.57

$41.15

$41.11

09/21/2018

Tap to view 10 drug drugs

Drug	Indication	Stage	News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)	Schizophrenia	Approved	FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early	Schizophrenia - young adults	Phase 3	Phase 3 initiation announced June 8, 2017.
ALKS 3831 - ENLIGHTEN-2	Schizophrenia	Phase 3	Phase 3 completion of enrollment announced April 26, 2018. Data due 4Q 2018.
BYDUREON	Type 2 diabetes	Approved	CRL received March 15, 2010.
Aristada	Schizophrenia	Approved	Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
ALKS 8700 (BIIB098)	Multiple sclerosis (MS)	Phase 3	NDA filing due 4Q 2018.
ALKS 6428	Opioid dependence	Phase 3	Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461	Major depressive disorder	PDUFA	NDA filed but Refusal To File Letter announced April 2, 2018. However, company announced April 16, 2018 that the NDA has been accepted with a PDUFA date of January 31, 2019. Advisory Committee Meeting likely 4Q 2018.
ALKS 3831 - ENLIGHTEN-1	Schizophrenia	Phase 3	Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230	Solid tumors	Phase 1	Phase 1 initial data due 2H 2018.

ALLK Allakos Inc.

$47.64

+2.6  +5.77%

42.1 million

$2 billion

7.73

1.4 million

271.1 thousand

5.04

-$26.61

$45.34

$45.04

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AK002	Severe Allergic Conjunctivitis	Phase 1	Phase 1 data due 1Q 2019.
AK002	Indolent Systemic Mastocytosis	Phase 1	Phase 1 data due 1Q 2019.
AK002	Chronic Urticaria	Phase 2	Phase 2 data due 1Q 2019.
AK002	Eosinophilic Gastritis	Phase 2	Phase 2 top-line data due mid-2019.

ALNA Allena Pharmaceuticals Inc.

$10.35

-1.07  -9.37%

20.8 million

$214.8 million

1.79

104.2 thousand

68.2 thousand

1.53

$3.19

$11.42

$11.42

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
ALLN-177	Enteric Hyperoxaluria	Phase 3	Data from first Phase 3 trial due 2H 2019.
ALLN-177	Primary hyperoxaluria	Phase 2	Phase 2 trial initiated March 2018 with interim data due 2H 2018 and top-line data due 2H 2019.

ALNY Alnylam Pharmaceuticals Inc.

$94.57

-0.64  -0.67%

100.7 million

$9.5 billion

5.22

798.7 thousand

951.7 thousand

0.84

$5.87

$95.29

$95.21

09/21/2018

Tap to view 13 drug drugs

Drug	Indication	Stage	News
ALN-CC5 (cemdisiran)	Atypical hemolytic-uremic syndrome (aHUS)	Phase 1/2	Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
Fitusiran	Hemophilia A and B	Phase 2	Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran	Acute hepatic porphyrias	Phase 3	Phase 3 completion of enrollment announced August 21, 2018 with interim analysis due late-September 2018. Full data due early 2019.
Inclisiran - ORION-9	Hypercholesterolemia	Phase 3	Phase 3 completion of enrollment announced February 20, 2018 enrollment to be completed 1H 2018. Data 3Q 2019.
ALN-HBV	Chronic hepatitis B virus (HBV)	Phase 1/2	Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
Lumasiran (ALN-GO1)	Primary Hyperoxaluria Type 1 (PH1)	Phase 3	Phase 1/2 positive data released November 11, 2017. Phase 3 trial to be initiated mid-2018 with data due 2019.
Patisiran	Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Approved	FDA Approval announced August 10, 2018.
Revusiran ENDEAVOUR	ATTR in patients with familial amyloidotic cardiomyopathy (FAC)	Phase 3	Phase 3 trial discontinued October 2016.
ALN-CC5	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 1/2	Phase 1/2 initial data presented at ASH 2016.
Fitusiran (ATLAS)	Hemophilia	Phase 3	Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
ALN-TTRsc02	ATTR amyloidosis	Phase 1	Phase 3 trial to be initiated late 2018.
Inclisiran - ORION-10	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION 11	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.

ALPN Alpine Immune Sciences Inc.

$6.18

-0.27  -4.19%

13.9 million

$85.6 million

2.08

28.2 thousand

17.2 thousand

1.64

$1.29

$6.42

$6.45

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
N91115	Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein	Phase 2	Phase 2 data released February 24, 2017 - primary endpoint not met.

ALRN Aileron Therapeutics Inc.

$2.87

-0.33  -10.31%

14.7 million

$42.3 million

0.39

68.1 thousand

108.7 thousand

0.63

$1.29

$3.20

$3.20

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ALRN-6924	Peripheral T-cell lymphoma (PTCL)	Phase 2a	Phase 2a interim data due 4Q 2018.
ALRN-6924	Solid tumors - cancer	Phase 1/2	Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
ALRN-6924	Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)	Phase 1b	Phase 1/1b interim data due 4Q 2018.

ALT Altimmune Inc.

$26.19

-0.04  -0.15%

42.8 thousand

$1.1 million

3.75

878.2 thousand

127 thousand

6.92

$1.05

$26.90

$26.23

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
HepTCell	Hepatitis B	Phase 1	Phase 1 data due early 4Q 2018.
NasoVAX	Flu vaccine	Phase 2	Phase 2 additional data released September 4, 2018.
NASOSHIELD	Anthrax	Phase 1	Phase 1 immunogenicity data two-dose cohort due 4Q 2018.

ALXN Alexion Pharmaceuticals Inc.

$121.99

-2.62  -2.10%

222.9 million

$27.2 billion

2.83

1.6 million

1.3 million

1.24

$3.10

$125.09

$124.61

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Eculizumab	Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Phase 3	Phase 3 enrollment complete with data due by the end of 2018.
ALXN1210	atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3	Phase 3 enrollment completed late May 2018 with data due early 2019.
ALXN1210	Paroxysmal nocturnal hemoglobinuria (PNH)	PDUFA priority review	PDUFA date under priority review February 18, 2019.
Eculizumab	Refractory generalized myasthenia gravis (gMG)	Approved	Approval announced October 23, 2017.

AMAG AMAG Pharmaceuticals Inc.

$20.65

-0.25  -1.20%

34.5 million

$711.9 million

20.46

1.2 million

541.8 thousand

2.25

$0.98

$20.90

$20.90

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Digoxin immune fab (DIF)	Severe preeclampsia in pregnant women	Phase 2/3	Phase 2/3 commencement of enrollment announced June 1, 2017.
Rekynda	Hypoactive sexual desire disorder (HSDD)	Phase 3	NDA filing due early 2018.
Rekynda (Bremelanotide)	Female sexual dysfunction (FSD)	PDUFA	PDUFA date March 23, 2019.
Feraheme	Adults with iron deficiency anemia (IDA)	Approved	Approval for sNDA filing announced February 5, 2018.
Makena - auto injector	Reduce the risk of preterm birth in women with a singleton pregnancy	Approved	Approval announced February 14, 2018.

AMGN Amgen Inc.

$205.10

  +0.00%

647.3 million

$132.8 billion

5.28

7.3 million

2.3 million

3.15

$8.91

$205.66

$205.10

09/21/2018

Tap to view 19 drug drugs

Drug	Indication	Stage	News
Tezepelumab	Asthma	Phase 3	Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial enrolling.
Prolia (denosumab)	Glucocorticoid-induced osteoporosis (GIOP)	Approved	Approval announced May 21, 2018.
KYPROLIS (ASPIRE)	Relapsed Multiple Myeloma	Approved	sNDA approval announced June 11, 2018.
Vectibix (Panitumumab)	Wild-Type RAS Metastatic Colorectal Cancer	Approved	sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	PDUFA	Approved September 14, 2017.
Corlanor	Chronic Heart Failure	Approved	Approved April 15, 2015.
Erenumab	Migraine	Approved	Approval announced May 17, 2018.
CNP 520	Alzheimer’s Disease	Phase 3	Phase 3 ongoing. Expected completion 2024.
Repatha	Cardiovascular disease	Approved	Approval announced December 1, 2017.
XGEVA	Multiple Myeloma	Approved	sBLA approval announced January 5, 2017.
KYPROLIS (ARROW)	Multiple Myeloma	sNDA Filing	sNDA filing announced August 27, 2018.
KYPROLIS (ENDEAVOR)	Relapsed Multiple Myeloma	Approved	sNDA approved January 17, 2018.
BLINCYTO	Ph+ R/R ALL	Approved	PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	Phase 3 enrolling.
ABP 980	Herceptin biosimilar	BLA Filing	BLA filing announced July 31, 2017.
ABP 710	REMICADE biosimilar - rheumatoid arthritis	Phase 3	Phase 3 data likely due 2H 2018.
Parsabiv	Secondary hyperparathyroidism (SHPT)	Approved	Approved February 7, 2017.
EVENITY (Romosozumab)	Osteoporosis	BLA Filing	CRL issued July 16, 2017. BLA resubmission announced July 13, 2018.
AMG 301	Migraine	Phase 2	Phase 2 data due by end of 2018.

AMPE Ampio Pharmaceuticals Inc.

$0.54

+0.03  +5.26%

106.5 million

$57.7 million

3.4

2.9 million

2.6 million

1.1

-$13.55

$0.52

$0.51

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Ampion	Osteoarthritis of the Knee	Phase 3	Noted August 7, 2018 that further trials required before filing BLA.
Optina	Diabetic Macula Edema	Phase 2b	Phase 2b data released May 2015 did not meet endpoints

AMPH Amphastar Pharmaceuticals Inc.

$19.18

+0.12  +0.63%

46.3 million

$887.2 million

11.34

586.7 thousand

144.4 thousand

4.06

$2.77

$19.10

$19.06

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Albuterol DPI	Asthma	Phase 2b
Naloxone Intranasal	Opioid overdose	CRL	CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol)	Asthma	CRL	CRL issued December 27, 2016.

AMRN Amarin Corporation plc

$2.99

+0.06  +2.05%

296.3 million

$886.1 million

3.34

4.3 million

3.6 million

1.18

-$12.46

$3.00

$2.93

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Vascepa REDUCE-IT outcomes trial	High Triglycerides With Mixed Dyslipidemia	Phase 3	Data due before the end of September 2018.

AMRX Amneal Pharmaceuticals Inc. Class A

$23.56

-0.63  -2.60%

298.5 million

$7 billion

4.97

860.8 thousand

1.3 million

0.68

$0.00

$24.06

$24.19

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
IPX203	Parkinson's disease	Phase 3	Phase 3 initiation announced May 7, 2018.

ANAB AnaptysBio Inc.

$92.80

+0.5  +0.54%

24 million

$2.2 billion

7.72

1.1 million

321.9 thousand

3.32

$7.83

$91.97

$92.30

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ANB020	Moderate-to-severe adult atopic dermatitis	Phase 2b	Phase 2b data due 2H 2019.
ANB020	Severe adult eosinophilic asthma	Phase 2a	Phase 2a data due 3Q 2018.
ANB019	Palmo-plantar pustular psoriasis	Phase 2	Phase 2 trial to be initiated in 2018 with data due 2H 2019.
ANB019	Generalized pustular psoriasis	Phase 2	Phase 2 data due early 2019.
ANB020	Nasal polyps	Phase 2	Phase 2 trial to be initiated by the end of 2018 with data due 2H 2019.

ANIK Anika Therapeutics Inc.

$41.02

+0.17  +0.42%

14.6 million

$598.2 million

26.49

268.4 thousand

133.5 thousand

2.01

$2.43

$40.84

$40.85

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Cingal	Osteoarthritis	Phase 3	Phase 3 trial did not meet primary endpoint - June 19, 2018.
Monovisc	Osteoarthritis	Approved	Approved Feb 2014
HYALOFAST	Cartilage defects of the knee	Phase 3	Phase 3 enrollment to be completed by the end of 2018.

ANTH Anthera Pharmaceuticals Inc.

$0.08

  +1.79%

26.2 million

$2 million

2.04

65.2 thousand

123.3 thousand

0.53

$0.37

$0.08

$0.08

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Sollpura - RESULT	Exocrine pancreatic insufficiency	Phase 3	Phase 3 data released March 12, 2018 did not meet primary endpoint.
Blisibimod	IgA nephropathy	Phase 2	Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Sollpura (liprotamase)	Cystic fibrosis who suffer from exocrine pancreatic insufficiency	Phase 3	Top-line data released December 27, 2016 - missed primary endpoint.
Blisibimod	Lupus	Phase 3	Phase 3 trial did not meet endpoints - November 10, 2016.

APHB AmpliPhi Biosciences Corporation

$0.92

+0.02  +2.79%

16.5 million

$15.1 million

9.09

136.1 thousand

124.5 thousand

1.09

$1.80

$0.97

$0.89

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AB-SA01	S. aureus bacteremia	Phase 2	Phase 1/2 trial planned for early 2019.

APLS Apellis Pharmaceuticals Inc.

$19.88

-0.09  -0.45%

56.2 million

$1.1 billion

8.91

419.2 thousand

243.9 thousand

1.72

$4.86

$20.00

$19.97

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
APL-2 subcutaneous	Complement-dependent Nephropathies (CDN)	Phase 2	Phase 2 monotherapy data due 2H 2018.
APL-2 subcutaneous	Auto-immune Hemolytic Anemia (AIHA)	Phase 2	Phase 2 monotherapy data due 1H 2018 (overdue - shifted to 3Q in the calendar).
APL-2 subcutaneous and eculizumab (Soliris)	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1b	Phase 1b eculizumab add-on and monotherapy expansion updates released June 2018.
APL-2 IV - FILLY	Geographic atrophy (GA)	Phase 3	Phase 3 trial to commence 2H 2018. Phase 2 18 month safety & efficacy data released February 22, 2018.
APL-2 subcutaneous	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 trial initiation announced June 26, 2018.

APRI Apricus Biosciences Inc.

$0.28

-0.01  -2.30%

23.4 million

$6.7 million

2.92

229.2 thousand

587.2 thousand

0.39

$1.24

$0.27

$0.29

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Vitaros	Erectile dysfunction	CRL	CRL issued for NDA resubmission - February 16, 2018. Noted April 16, 2017 two further Phase 3 trials required. Will need partner to finance trials.

APTO Aptose Biosciences Inc.

$2.60

+0.01  +0.39%

34.4 million

$89.5 million

2.67

121.4 thousand

205 thousand

0.59

$5.20

$2.60

$2.59

09/21/2018

Tap to view 1 drug drugs

Drug	Indication	Stage	News
APTO-253	Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)	Phase 1b	Phase 1b clinical hold released June 29, 2018.

APTX Aptinyx Inc.

$26.69

-0.74  -2.70%

33.5 million

$894 million

6.66

1.9 million

92.5 thousand

20.17

$5.09

$27.46

$27.43

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
NYX-458	Parkinson’s Disease Cognitive Impairment (healthy volunteers)	Phase 1	Phase 1 data due 1H 2019.
NYX-2925	Fibromyalgia	Phase 2	Phase 2 data due 1H 2019.
NYX-2925	Neuropathic Pain Associated with Diabetic Peripheral Neuropathy	Phase 2	Phase 2 data due 1H 2019.
NYX-2925	Healthy volunteers	Phase 1	Pharmacodynamic/ biomarker data due 2H 2018.

APVO Aptevo Therapeutics Inc.

$4.95

-0.16  -3.13%

22.7 million

$112.2 million

1.61

62.5 thousand

107.1 thousand

0.58

$2.00

$5.13

$5.11

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
APVO414	Castration-resistant prostate cancer	Phase 1	Phase 1 data due by the end of 2018.
Otlertuzumab	Relapsed or refractory peripheral T-cell lymphoma	Phase 2	Phase 2 top-line data due by end of 2018.
APVO436	Acute myeloid leukemia (AML)	Phase 1	Phase 1 dosing to commence 4Q 2018.

AQST Aquestive Therapeutics Inc.

$16.33

+0.02  +0.12%

24.9 million

$407 million

0.15

705.9 thousand

177 thousand

3.99

-$17.75

$16.39

$16.31

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AQST-117	Amyotrophic Lateral Sclerosis	Phase 3	NDA filing due 1H 2019.
Sympazan	Lennox-Gastaut Syndrome	Approved	Tentative approval announced August 31, 2018.
Libervant - AQST-203	Epileptic seizures	Phase 3	NDA filing due 2018.

AQXP Aquinox Pharmaceuticals Inc.

$2.93

+0.06  +2.09%

23.5 million

$69 million

0.74

171 thousand

456.5 thousand

0.37

$0.76

$2.90

$2.87

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Rosiptor (AQX-1125)	Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Phase 2	Phase 2 trial has been discontinued.
AQX-1125 LEADERSHIP	Bladder pain syndrome/interstitial cystitis (BPS/IC)	Phase 3	Phase 3 data released June 27, 2018. Primary endpoint not met.
AQX-1125 KINSHIP	Atopic dermatitis (AD)	Phase 2	Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 FLAGSHIP	Chronic obstructive pulmonary disease (COPD)	Phase 2	Phase 2 trail failed - July 2015

ARDM Aradigm Corporation

$1.17

-0.05  -4.10%

15.2 million

$17.8 million

11.3

16.7 thousand

16.9 thousand

0.98

-$0.89

$1.24

$1.22

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Sumavel	Migraine	Approved	Approval granted July 16, 2009.
Linhaliq (Pulmaquin)	Non-cystic fibrosis bronchiectasis (non-CF BE).	CRL	Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.

ARDS Aridis Pharmaceuticals Inc.

$12.01

-1.06  -8.11%

$

0.03

18.5 thousand

0

-$1.35

$12.94

$13.07

09/21/2018

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AR-301 (Salvecin)	Staphylococcus aureus	Phase 3	Phase 3 trial to be initiated 2H 2018 with interim data 2H 2019 and final data in 2020.
AR-105 (Aerucin)	Pseudomonas aeruginosa	Phase 2	Phase 2 interim data due 1H 2019.
AR-101 (Aerumab)	Pseudomonas aeruginosa	Phase 2	Phase 2/3 trial to be initiated 2H 2019.

ARDX Ardelyx Inc.

$4.15

-0.05  -1.19%

62.1 million

$257.5 million

1.74

957.8 thousand

342 thousand

2.8

$1.58

$4.15

$4.20

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Tenapanor (T3MPO-2)	Constipation-predominant irritable bowel syndrome (IBS-C)	NDA Filing	NDA filing announced September 13, 2018.
RDX7675	Hyperkalemia	Phase 2	Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Tenapanor	Hyperphosphatemia in end-stage renal disease (ESRD) patients	Phase 3	Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Tenapanor (T3MPO-1)	Constipation-predominant irritable bowel syndrome (IBS-C)	Phase 3	Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.

ARGX argenx SE

$77.96

-2.24  -2.79%

32.5 million

$2.5 billion

3.32

614.8 thousand

185.2 thousand

3.32

$6.52

$78.42

$80.20

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Efgartigimod (ARGX-113)	Pemphigus vulgaris (PV)	Phase 2	Phase 2 interim data released June 20, 2018, disease control observed in 4/6 patients. Full data due 1H 2019.
ARGX-110	Relapsed/refractory cutaneous T-cell lymphoma (CTCL)	Phase 2	Phase 2 interim data ASH 2017 - of 22 patients 1 CR, 2 PRs, 10 SD. Full data due by the end of 2018.
ARGX-110	Acute myeloid leukemia (AML)	Phase 1/2	Phase 1/2 interim data at ASH 2017 - all six patients showed response including 3/6 with complete remission. Full data due by the end of 2018.
ARGX-113	Immune thrombocytopenia (ITP)	Phase 2	Phase 2 released September 17, 2018 - well-tolerated.
Efgartigimod	Myasthenia gravis (MG)	Phase 3	Phase 3 trial initiation announced September 5, 2018.

ARLZ

$0.00

  +0.00%

$

0

$0.00

$0.00

$0.00

08/22/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
VIMOVO	Gastric ulcers	Approved	Approved April 30, 2010.
YOSPRALA (PA32540/PA8140)	Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers	Approved	Approval announced September 15, 2016.

ARMO ARMO BioSciences Inc.

$0.00

  +0.00%

30.4 million

$

0.82

426.6 thousand

0

$9.69

$0.00

$0.00

09/21/2018

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AM0010 (PEG-IL-10) and Nivolumab - Cypress 2	Non-small cell lung cancer (NSCLC)	Phase 2b	Phase 2b initiation announced March 29, 2018 with preliminary data due over the course of 2018.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1	Non-small cell lung cancer (NSCLC)	Phase 2b	Phase 2b initiation announced March 29, 2018 with preliminary data due end of 2018.
AM0010 (PEG-IL-10)	Solid tumors	Phase 1b	Phase 1/1b trial ongoing. Data presented at ASCO June 2018.
AM0010 (PEG-IL-10)	pancreatic ductal adenocarcinoma (PDAC)	Phase 3	Phase 3 interim analysis March 26, 2018. Trial to continue. Second analysis and final data due 2020.

ARNA Arena Pharmaceuticals Inc.

$43.75

+0.67  +1.56%

49.3 million

$2.2 billion

5.27

862.3 thousand

495.3 thousand

1.74

$3.87

$43.02

$43.08

09/21/2018

Tap to view 8 drug drugs

Drug	Indication	Stage	News
Etrasimod	Primary biliary cholangitis (PBC)	Phase 2	Phase 2 initiated 2017.
Etrasimod	Pyoderma gangrenosum (PG)	Phase 2	Phase 2 trial initiated March 2017.
Etrasimod	Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)	Phase 2	Phase 2 trial initiated March 2017.
Lorcaserin	Obesity	Approved	Approved June 27, 2012.
Olorinab (APD371)	Pain associated with Crohn's disease	Phase 2	Phase 2 data due late-September 2018.
Lorcaserin	Smoking cessation	Phase 2	Phase 2 initiated March 2014. Data released Nov 2014
Etrasimod	Ulcerative colitis	Phase 2	Phase 2 data released March 19, 2018 - primary and secondary endpoints met.
Ralinepag	Pulmonary Arterial Hypertension	Phase 3	Phase 3 enrollment to commence August 2018.

ARPO Aerpio Pharmaceuticals Inc.

$3.39

-0.31  -8.38%

40.6 million

$137.6 million

0.14

622.9 thousand

68.5 thousand

9.1

$2.87

$3.70

$3.70

09/21/2018

Tap to view 2 drug drugs

Drug	Indication	Stage	News
AKB-4924	Ulcerative Colitis	Phase 1	Phase 1 multiple ascending dose data due 2H 2018.
AKB-9778 - TIME 2B	Non-Proliferative Diabetic Retinopathy	Phase 2	Phase 2 top-line data due 2Q 2019.

ARQL ArQule Inc.

$5.08

-0.07  -1.36%

108.8 million

$552.8 million

4.26

7.8 million

1.3 million

6.03

$20.32

$5.19

$5.15

09/21/2018

Tap to view 6 drug drugs

Drug	Indication	Stage	News
ARQ 092	Overgrowth Diseases	Phase 1/2	Phase 1/2 trial has commenced enrollment - May 4, 2017.
Derazantinib (ARQ 087)	intrahepatic cholangiocarcinoma (iCCA)	Phase 3	Phase 1/2 interim data due 2019.
Tivantinib (ARQ 197) METIV-HCC trial	Previously treated Inoperable Hepatocellular Carcinoma cancer	Phase 3	Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Miransertib - ARQ 092	Solid tumors	Phase 1b	Phase 1b data due 2019.
ARQ 531	B-cell malignancies	Phase 1a	Phase 1a data due 2H 2018.
ARQ 751	Solid tumors	Phase 1	Phase 1a data due 2H 2018.

ARRY Array BioPharma Inc.

$15.30

+0.41  +2.75%

212.9 million

$3.3 billion

6.55

5.2 million

2.1 million

2.5

$14.85

$14.82

$14.89

09/21/2018

Tap to view 10 drug drugs

Drug	Indication	Stage	News
ARRY-382 and Keytruda	Non-small cell lung cancer	Phase 1/2	Phase 1/2 initial efficacy data presented in poster November 10, 2017 at SITC.
Selumetinib - ASTRA	Thyroid cancer	Phase 3	Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - SELECT-1	Differentiated thyroid cancer	Phase 3	Phase 3 trial did not meet its primary endpoint - August 2016
Binimetinib - COLUMBUS	BRAF mutant melanoma cancer	Approved	Approval announced June 27, 2018.
ARRY 797	LMNA A/C-related dilated cardiomyopathy (DCM)	Phase 3	Phase 3 trial initiated 1Q 2018.
Binimetinib (NEMO)	NRAS melanoma - cancer	Phase 3	PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC	BRAF-Mutant Colorectal Cancer	Phase 3	Phase 3 top-line data due 1H 2019.
Binimetinib - MILO	Recurrent low-grade serous ovarian cancer (LGSOC)	Phase 3	Phase 3 trial discontinued April 2016
Binimetinib and nivolumab	Colorectal cancer	Phase 1	Phase 1 planned.
Binimetinib and avelumab/talazoparib	Non-small cell lung cancer (NSCLC) and pancreatic cancer	Phase 1b	Phase 1b trial to be initiated 3Q 2018.

ARWR Arrowhead Pharmaceuticals Inc.

$17.77

-1.11  -5.88%

88 million

$1.6 billion

10.47

3.1 million

2.2 million

1.4

$15.32

$18.88

$18.88

09/21/2018

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ARC-AAT	Alpha-1 antitrypsin deficiency (AATD)	Phase 2	Announced that development will be discontinued - November 29, 2016.
ARC-521	Chronic Hepititis B (HBV)	Phase 1/2	Announced that development will be discontinued - November 29, 2016.
ARC-520 injection in combination with entecavir or tenofovir	Chronic Hepititis B (HBV)	Phase 2	Announced that development will be discontinued - November 29, 2016.
ARO-HBV	Hepatitis B (HBV)	Phase 1/2	Phase 1/2 completion of dosing in for single dose portion of trial an